<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03196219</url>
  </required_header>
  <id_info>
    <org_study_id>C3J17-206-00</org_study_id>
    <nct_id>NCT03196219</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects</brief_title>
  <acronym>C3J17-206-00</acronym>
  <official_title>A Phase 2, Open-label and Single-Blind Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip Administered in Multiple Doses to Adolescent and Adult Dental Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C3 Jian, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C3 Jian, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label and single-blind phase 2 study to evaluate the oral microbiology, safety and
      tolerability of multiple C16G2 Varnish and Strip applications in male and female dental
      subjects 12-75 years of age. The study will compare multiple study drug administrations of
      C16G2 Varnish and/or C16G2 Strip in three study arms.

      In Study Arm 1 eight subjects will be enrolled in an open-label manner and will receive a
      daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip
      administered over 7 days. Following the three C16G2 Varnish applications, each subject will
      receive 7 days of AM and PM dosing with C16G2 Strip and will be followed for microbiology for
      up to 2 months after the last study drug administration.

      Study Arm 2 will enroll 12 subjects in a single-blind manner. Subjects will receive four
      C16G2 Varnish or Placebo applications over 7 days, followed by 3 additional weekly varnish
      administrations. Subjects will be followed for microbiology for up to 2 months after the last
      study drug administration.The treatment allocation will be 1:1 (6 subjects receiving C16G2
      Varnish, 6 subjects receiving Placebo).

      Study Arm 3 will be initiated based on the Sponsor's review of all microbiology data up to
      two week post last study drug administration from Study Arm 2. If initiated, Study Arm 3 will
      enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2
      Varnish over 10 days, for a total of 10 doses and will be followed for microbiology for up to
      2 months after the last study drug administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label and single-blind phase 2 study to evaluate the oral microbiology, safety and
      tolerability of multiple C16G2 Varnish and Strip applications in male and female dental
      subjects 12-75 years of age.

      The study will compare multiple study drug administrations of 13.6 miligrams (mg) of C16G2
      Varnish and 9.2 mg of C16G2 Strip in three study arms. Before dosing of study drug, eligible
      subjects will receive professional dental prophylaxis between Days -7 and -2.

      In Study Arm 1 eight subjects will be enrolled in an open-label manner and will receive a
      daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip
      administered over 7 days. C16G2 Varnish will be applied with a small brush typically used in
      dental varnish administration. Following the three C16G2 Varnish applications, each subject
      will receive 7 days of AM and PM dosing with C16G2 Strip. To evaluate the durability of S.
      mutans suppression, study subjects will be followed for microbiology for up to 2 months after
      the last study drug administration.

      Study Arm 2 will enroll 12 subjects in a single-blind manner. Subjects will receive four
      C16G2 Varnish or Placebo applications over 7 days (Days 0, 2, 5 &amp; 7), followed by 3
      additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects
      receiving C16G2 Varnish, 6 subjects receiving Placebo). To evaluate the durability of S.
      mutans suppression, study subjects will be followed for microbiology for up to 2 months after
      the last study drug administration.

      Study Arm 3 will be initiated based on the Sponsor's review of all microbiology data up to
      two week post last study drug administration from Study Arm 2.

      If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will
      receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses. To
      evaluate the durability of S. mutans suppression, study subjects will be followed for
      microbiology for up to 2 months after the last study drug administration.

      Clinic visits in Study Arm 1 include Visit 1 (Screening/Days -30 to -1), Visit 2
      (Prophylaxis/Day -7 to -2), Eligibility Confirmation, Baseline &amp; First C16G2 Varnish Dosing
      at Visit 3, Visits 4 &amp; 5 (C16G2 Varnish Administration), Visits 6-19 (AM &amp; PM C16G2 Strip
      Administration), Follow-up Visits 20 &amp; 21 (Safety and Microbiology) and Follow-up Visits
      22-24 (Microbiology only).

      Clinic visits in Study Arm 2 include Visit 1 (Screening/Days -30 to -1), Visit 2
      (Prophylaxis/Day -7 to -2), Eligibility Confirmation, Baseline &amp; First C16G2 Varnish or
      Placebo Dosing at Visit 3, Visits 4-9 (C16G2 Varnish or Placebo Administration), Follow-up
      Visits 10 &amp; 11 (Safety and Microbiology) and Follow-up Visits 12-14 (Microbiology only).

      Clinic visits in Study Arm 3 include Clinic Visit 1 (Screening/Days -30 to -1), Visit 2
      (Prophylaxis/Day -7 to -2), Eligibility Confirmation, Baseline &amp; First C16G2 Varnish Dosing
      at Visit 3, Visits 4-12 (C16G2 Varnish Administration), Follow-up Visits 13 &amp; 14 (Safety and
      Microbiology) and Follow-up Visits 15-17 (Microbiology only).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Actual">January 10, 2018</completion_date>
  <primary_completion_date type="Actual">November 22, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Study Arms 1 and 2 will be enrolled in parallel followed by Study Arm 3.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>In the single-blind Study Arm 2, active and placebo will be identical in appearance and labeled in a blinded fashion</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial Activity of C16G2</measure>
    <time_frame>Evaluated over up to 2 months</time_frame>
    <description>To assess the targeted antimicrobial activity of C16G2 applications as measured by a reduction in Streptococcus mutans in saliva and dental plaque</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Oral Bacterial Levels</measure>
    <time_frame>1 day post last study drug administration</time_frame>
    <description>Total bacterial levels will be evaluated by measuring CFU/mL counts of salivary and plaque bacteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of C16G2 Administrations assessed by performing targeted physical examinations, oral cavity exams, taking vital signs and collection of adverse events</measure>
    <time_frame>Up to 7 days post last study drug administration</time_frame>
    <description>Safety will be assessed by performing targeted physical examinations, oral cavity exams, taking vital signs and collection of adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Dental Caries</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eight subjects will be enrolled in an open-label manner and will receive a daily dose of C16G2 Varnish application over 3 days followed by 14 doses of C16G2 Strip administered over 7 days. Following the three C16G2 Varnish applications, each subject will receive 7 days of AM and PM dosing with C16G2 Strip.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twelve subjects will be enrolled in a single-blind manner. Subjects will receive four C16G2 Varnish or Placebo applications over 7 days (Days 0, 2, 5 &amp; 7), followed by 3 additional weekly varnish administrations. The treatment allocation will be 1:1 (6 subjects C16G2 Varnish, 6 subjects Placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If initiated, Study Arm 3 will enroll 6 subjects in an open-label manner. Subjects will receive daily single doses of C16G2 Varnish over 10 days, for a total of 10 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C16G2</intervention_name>
    <description>C16G2</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <other_name>Antimicrobial Peptide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Varnish Placebo</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females, 12-75 years of age

          2. Adults subjects provide written informed consent and adolescent subjects give written
             or verbal assent, as appropriate, and parent(s) or legal guardian(s) give written
             informed consent

          3. Female subjects of childbearing potential must agree to use one of the following forms
             of contraception from screening through the last study visit: hormonal (oral, implant,
             or injection) begun &gt;30 days prior to screening; barrier (condom, diaphragm, or
             cervical cap with spermicide); intrauterine device (IUD). Acceptable contraceptive
             options may also include abstinence, relationship with a same sex partner or partner
             who has had a vasectomy at least six (6) months prior to the screening visit

          4. Negative urine pregnancy test in all females of childbearing potential (past menarche)

          5. Male subjects of sexual activity age: willing to use contraception or abstain from
             sexual activity beginning with the first exposure to study drug and continuing until
             discharged from the study due to completion or Early Termination

          6. Healthy, as determined by the Investigator (in consultation with the Medical Monitor,
             as needed), based on medical and dental history, concurrent illnesses, laboratory
             results, concomitant medications, oral cavity assessment, and targeted physical
             examination (general, extraoral, head and neck) during Screening.

             Note: Subjects on a stable dose of medication may be eligible for screening and will
             be assessed by the medical monitor on a case-by-case basis.

          7. Have a minimum of 12 bicuspids and molars with a minimum of 8 molars and bicuspids NOT
             having restorations, crowns or sealants

          8. Demonstrated ability to expectorate â‰¥2 mL of stimulated saliva in 5 minutes

          9. Have a salivary S. mutans of 1.0 x 105 CFUs/mL or greater at Screening using MSB agar
             plating

         10. Willing to refrain from using non-study dentifrice and other non-study oral care
             products (oral care rinses, fluoride products, etc.) during the study

         11. Willing to postpone elective dental procedures (e.g., dental cleanings) between
             Screening and final post-treatment visit (End of Study or Early Termination)

         12. Willing and able to comply with oral hygiene and diet instructions

         13. Able to communicate with the Investigator/study center personnel, understand and
             comply with the study requirements, and willing to return for protocol-specified
             visits at the appointed times

        Exclusion Criteria:

          1. Advanced periodontal disease

          2. Active caries lesion(s) within 30 days prior to study drug administration (confirmed
             by comprehensive caries examination including standard radiographs). Subjects
             presenting with insipient, non-cavitated lesion(s) are not excluded.

             Note: If radiographs are deemed appropriate for the study and taken within 6 months
             prior to the Screening visit, these may be used for determining eligibility and are
             not required to be repeated at Screening

          3. Partially erupted teeth where the entire crown is not erupted or an operculum is
             present

          4. Medical condition (e.g., artificial heart valve, history of infective endocarditis,
             cardiac transplant with valvular dysfunction, congenital heart disease or total joint
             replacement) for which antibiotics are recommended prior to dental visits and/or
             procedures

          5. Pathologic lesions of the oral cavity (suspicious or confirmed)

          6. Full dentures or permanent orthodontic appliances, e.g., braces, buccal or lingual
             brackets. Note: Partial dentures, removable retainers and night guards are not
             excluded, provided that they are cleaned regularly throughout the duration of the
             study

          7. Use of systemic antibiotics, topical oral antibiotics, any immunosuppressant therapy,
             and steroids, beginning 30 days prior to Screening until the end of study
             participation

          8. Medical history indicating the woman is pregnant, breastfeeding/lactating or has a
             positive urine pregnancy test

          9. Participation in a clinical trial or receipt of a non-FDA approved therapy within 30
             days prior to study drug administration (depending on the specifics, participation in
             an observational study is not necessarily excluded)

         10. Participation in a previous C16G2 clinical trial having received either C16G2 Strip,
             C16G2 Varnish or Placebo Varnish

         11. Presence of any condition or concurrent illness, which in the opinion of the
             Investigator, would compromise normal immune function (e.g., diabetes, rheumatoid
             arthritis, lupus, liver disease, organ transplant, etc.), interfere with the use of
             study dentifrice and oral care products, or interfere with the ability to comply with
             study requirements, or jeopardize the safety of the subject or the validity of the
             study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>John F. Pittaway, DMD</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2017</study_first_submitted>
  <study_first_submitted_qc>June 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2017</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dental Caries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

